Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07116616 · ClinicalTrials.gov registry record · Phase 1
A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma
A Phase 1 study of Relapsed or Refractory Multiple Myeloma, sponsored by ModernaTX.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 166
- Enrollment target
- 10
- Study locations
NCT07116616: Recruiting Phase 1 study of Relapsed or Refractory Multiple Myeloma, sponsored by ModernaTX.
NCT07116616 is a Phase 1 study of Relapsed or Refractory Multiple Myeloma that is actively recruiting participants, run by ModernaTX. The registered enrollment target is 166 participants, below the 326-participant average among 10 other Relapsed or Refractory Multiple Myeloma trials with a reported enrollment target (49% lower). The trial reports 10 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07116616, a Phase 1 study of Relapsed or Refractory Multiple Myeloma, is actively recruiting participants, sponsored by ModernaTX.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 166 participants
- Enrollment target
- 10
- Study locations
Study Summary
The purpose of this study is to evaluate the safety and tolerability of mRNA-2808 in participants with relapsed or refractory multiple myeloma (RRMM).
Conditions Studied
Interventions
- DRUG mRNA-2808
Study Locations (10)
New York
- Tisch Cancer Institute at Mount Sinai - New York
- Memorial Sloan-Kettering Cancer Center - New York
Alabama
- University of Alabama at Birmingham Hospital - Birmingham
California
- UCSF - San Francisco
Georgia
- Emory University Hospital - Atlanta
Massachusetts
- Mass General Brigham - Boston
North Carolina
- Atrium Health Levine Cancer Institute - Charlotte
Pennsylvania
- Penn Medicine - Philadelphia
Tennessee
- Sarah Cannon Research Institute - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 166 participants |
| Start Date | 2025-09-30 |
| Est. Completion | 2032-06-17 |
| Phase | Phase 1 |
What NCT07116616 shows while recruiting
NCT07116616 is an interventional study that assigns participants to a tested intervention. The registered 166 participants enrollment target is mid-sized for trials with a published cap, below the 326-participant average among 10 other Relapsed or Refractory Multiple Myeloma trials with a reported enrollment target (49% lower).
The record links to 1 condition, with Relapsed or Refractory Multiple Myeloma appearing as the primary indexed condition, and to 1 intervention - of which mRNA-2808 is the first listed.
NCT07116616 lists 10 locations in 9 states (New York, Alabama, California).
Frequently Asked Questions
What is clinical trial NCT07116616 about?
NCT07116616 is a clinical study titled "A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma". The purpose of this study is to evaluate the safety and tolerability of mRNA-2808 in participants with relapsed or refractory multiple myeloma (RRMM).
What is the current status of trial NCT07116616?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 166 participants. The study started on 2025-09-30. Estimated completion is 2032-06-17.
What conditions does trial NCT07116616 study?
This clinical trial studies the following conditions: Relapsed or Refractory Multiple Myeloma.
What interventions are being tested in trial NCT07116616?
The interventions under investigation include: mRNA-2808 (DRUG).
Who is sponsoring clinical trial NCT07116616?
This trial is sponsored by ModernaTX, which has 90 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07116616 being conducted?
This trial has 10 study locations across Alabama, California, Georgia, Massachusetts, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Relapsed or Refractory Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07116616's enrollment target sits among peer trials
166 6th of 10 higher than 5 of 10 other Relapsed or Refractory Multiple Myeloma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Relapsed or Refractory Multiple Myeloma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 1
-
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis
RECRUITING · Phase 1
-
A Study Comparing Pre- and Post-Change Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
ACTIVE NOT RECRUITING · Phase 1
-
Cabozantinib (XL184) in Patients With Relapsed or Refractory Myeloma
COMPLETED · Phase 1
-
Study to Evaluate the Safety and Efficacy of Anti-CD38 CAR-T in Relapsed or Refractory Multiple Myeloma Patients
COMPLETED · Phase 1
-
A Phase I Study Of Thymoglobulin In Patients With Relapsed Or Refractory Multiple Myeloma
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02747303 · 166 participants · Phase 2
Frameless Stereotactic Radiosurgery for Intact Brain Metastases
- NCT03806283 · 166 participants
Mechanisms of Pregnancy Vascular Adaptations
- NCT04040452 · 166 participants · Phase 4
Continuous vs Intermittent Ketorolac for Pain Control in Peds CV Surgery
- NCT04375813 · 166 participants · Phase 2
Trial of Encapsulated Rapamycin (eRapa) for Bladder Cancer Prevention
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI